Welcome to BioSeeker Group!

Triple Analysis: Leukemia, Lymphoma and Peptides

Additional Information

Published Date Jan 7, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3114
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Leukemia, Lymphoma and Peptides in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Leukemia and Lymphoma and by the compound strategy of Peptides.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Lymphoma and Peptides.

    To find out more about Triple Analysis: Leukemia, Lymphoma and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Lymphoma and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Leukemia and Lymphoma and by the compound strategy of Peptides. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Leukemia
The leukemia report part comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 investigators, from Ceased to Marketed. This part extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and and eight subindications of leukemia.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

Part II: Lymphoma
The lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and and five subindications of lymphoma.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Leukemia
5.1 The Scope of this Report 29
6 Consider the Therapeutic Target Among Leukemia Drugs for the Highest Therapeutic Outcome and Return on Investment (204 Drug Targets) 33-443
7 Emerging New Products to Established Ones: Drug Target Strategies of Leukemia Drugs by their Highest Stage of Development (193 Drug Target Strategies and 313 Leukemia Drugs) 444-727
8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Drugs by Compound Strategy (8 Compound Strategies) 679-728
9 Selecting Subindication for Leukemia Drugs (8 Subindications of Leukemia) 729-762
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Leukemia Drug Pipeline by Investigator (186 Companies) 763-1,129
11 Disclaimer 1130
12 Drug Index 1131
13 Company Index 1140
Figures: Includes 6 Figures
Tables: Includes 253 Tables
Total Number of Pages: 1,147

Part II: Lymphoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 30-387
7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs) 388-596
8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies) 597-636
9 Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma) 637-657
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies) 658-938
11 Disclaimer 939
12 Drug Index 940
13 Company Index 948
Figures: Includes 6 Figures
Tables: Includes 222 Tables
Total Number of Pages: 954

Part III: Peptides
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388
10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications) 391-475
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001
12 Disclaimer 1002
Figures: Includes 5 Figures
Tables: Includes 232 Tables
Total Number of Pages: 1,013

This Report Includes the Following Companies:
3M Pharmaceuticals
4SC
7TM Pharma
Abbott
Abiogen
Acceleron Pharma
Actinium Pharmaceuticals
Advaxis
AEgera
AEterna Zentaris
Affimed Therapeutics
Affymax
Agenus
Aida Pharmaceuticals
Aileron Therapeutics
Alexion
Alfa Wassermann
Alfacell
Allos Therapeutics
Allostera
Allosterix
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
Amgen
Anchor Therapeutics
AngioChem
Angstrom Pharmaceuticals
Antisoma
AplaGen Biopharmaceuticals
ApopLogic Pharmaceuticals
Apricus Biosciences
Arca biopharma
Ardana
Ariad
Arno Therapeutics
Array BioPharma
Asahi Kasei Pharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
Baxter International
Bayer
Benitec
Bio-Path Holdings
Biocon
BioCryst Pharmaceuticals
Bioenvision
Biogen Idec
Biokine Therapeutics
Biolex
BioSante
Bioton
Boehringer Ingelheim
Borean Pharma
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Camurus
CanBas
Cancer Advances
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Celator Pharmaceuticals
Celecure
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celltrion
Cephalon
Chemokine Therapeutics
Chiasma
Choongwae
CJ Corp
Clavis Pharma
Cleveland BioLabs
Clinuvel
Compugen
Cornerstone Pharmaceuticals
CSL
Curacyte
Curaxis
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
CytImmune Sciences
Cytokinetics
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Debiopharm
Deciphera Pharmaceuticals
Dendreon
DiaMedica
Digna Biotech
Dong-A
Dongkook Pharm
Dr Reddy’s
Dynavax Technologies
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
Endo Pharmaceuticals
Enkam Pharmaceuticals
EntreMed
Enzon
EpiCept
Epizyme
Erimos
Esperance Pharmaceuticals
Exelixis
ExonHit Therapeutics
Favrille
Forma Therapeutics
Formula Pharmaceuticals
Galena Biopharma
Gemin X Biotechnologies
Genencor
Genentech
Generex
Genmab
GENova Biotherapeutics
Genovax
GenPat77
Genta
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
Glide Pharma
Gliknik
GlycoGenesys
GlycoMimetics
GP Pharm
Gryphon Therapeutics
Hanmi
Hayashibara
Heber Biotec
HemaQuest
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
IDM Pharma
IGF Oncology
IkerChem
ImClone Systems
Immune Pharmaceuticals
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
Immunotope
ImmuPharma
Incyte Corporation
InDex Pharmaceuticals
Inex
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insys Therapeutics
Intas Biopharmaceuticals
Intracel
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
Italfarmaco
Johnson & Johnson
KAEL-GemVax
KaloBios
Kanisa
Karyon-CTT
Kinex
Kirax
Kissei
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
LFB Biotechnologies
LG Life Sciences
Ligand
Lorus Therapeutics
MacroGenics
Marillion Pharmaceuticals
MAT Biopharma
MaxCyte
MaxoCore Pharmaceuticals
MBiotec
Meda
MediGene
MedImmune
Mediolanum
Memgen
Merck & Co
Merck KGaA
MethylGene
Micromet
MolMed
Mologen
Nektar Therapeutics
Nemod Biotherapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurobiological Technologies
Nidus Laboratories
NIH
Nippon Shinyaku
Non-industrial source
Novartis
Novogen
Noxxon
NPS Pharmaceuticals
Nycomed Pharma
Onconova
OncoTherapy Science
Oncothyreon
OSI Pharmaceuticals
Otsuka
Pepscan Therapeutics
Peptagen
PepTx
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Philogen
PIERIS Proteolab
Pierre Fabre
Piramal
Plexxikon
Portola Pharmaceuticals
Prochon Biotech
ProMetic Life Sciences
ProNAi Therapeutics
Protagonist
Q Chip
QLT
Raptor Pharmaceutical
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Reliance Life Sciences
Rigel
Sangamo BioSciences
Sanofi
Sanofi-Aventis
Santaris Pharma
Sarepta Therapeutics
Sareum
SBI Biotech
SBIO
SciClone Pharmaceuticals
Seattle Genetics
Selvita
Semafore Pharmaceuticals
Sepal Pharma
Serometrix
Servier
Shenogen
Shire
Sidus
Soligenix
Southern Research Institute
Spectrum Pharmaceuticals
Spirogen
Stemline Therapeutics
SuperGen
SuppreMol
Swedish Orphan Biovitrum
SymBio Pharmaceuticals
Symbiotec
Synageva BioPharma
Synta Pharmaceuticals
Syntrix
Tactic Pharma
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
Targa Therapeutics
TargeGen
TeGenero
Tekmira Pharmaceuticals
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
Titan Pharmaceuticals
TopoTarget
Transgene
Trion Pharma
Unigene
United Biomedical
Vaccinex
Valeant
Vaxil BioTherapeutics
Vaxon Biotech
VentiRx Pharmaceuticals
Vertex Pharmaceuticals
Wilex
Vion Pharmaceuticals
VioQuest Pharmaceuticals
XBiotech
Xencor
Xigen
Yakult Honsha
Yamasa Corporation
Zelos Therapeutics
Zenotech
Zensun
Zenyaku Kogyo
A Shortlist of Drugs Included are:
131I-tositumomab
A6
abarelix
ABT-510
AEZS-108
afamelanotide
alemtuzumab
amonafide malate
amrubicin hydrochloride
amsacrine
angiopep+paclitaxel
barasertib
belinostat
bexarotene
bisantrene
bortezomib
bosutinib
brentuximab vedotin
CBP-501
cladribine
clofarabine
corticorelin acetate
CSF-GM
cytarabine ocfosfate
cytarabine, injectable
dasatinib
daunorubicin
decitabine
denileukin diftitox
deslorelin
E-75
elacytarabine
elliptinium acetate
emepepimut-S
enocitabine
enzastaurin hydrochloride
EP-100
epirubicin
everolimus
FPI-01
galiximab
gemtuzumab ozogamicin
goserelin
GV-1001
GX-301
HBP-347
Her-2/Neu peptides
histamine dihydrochloride
histrelin
ibritumomab tiuxetan
idarubicin
imatinib mesilate
imMucin
inotuzumab ozogamicin
interferon
interferon (alpha-N1)
interferon (alpha)
interferon (alpha2)
interferon (alpha2a)
interferon (alpha2b)
interferon (alpha2c)
interferon (gamma)
interferon alfa-2b
interferon alpha-2b
IPP-204106
irinotecan hydrochloride
ISA-P53-01
kahalalide F
lanreotide
lestaurtinib
leukemia vaccine
leuprolide
leuprolide acetate
leuprorelin
lumiliximab
MDX-1379
midostaurin
mitoxantrone
NAFB001
netupitant
nilotinib
obinutuzumab
oblimersen sodium
octreotide
octreotide, LAR
ofatumumab
ON-01910
OTS-102
ozarelix
panobinostat
pasireotide
pasireotide LAR
peginterferon alfa-2b
pentostatin
pixantrone
plitidepsin
polyclonal antibody stimulator
pralatrexate
razoxane
Reditux
rhIFN-alpha
rindopepimut
rituximab
romidepsin
romurtide
sobuzoxane
sotatercept
Survivac
tamibarotene
temsirolimus
teniposide
thymalfasin
tipifarnib
TM-30339
vapreotide, immediate-release
vitespen
vosaroxin
VX-001
zanolimumab
zorubicin

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Lymphoma and Peptides.
    To find out more about Triple Analysis: Leukemia, Lymphoma and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Lymphoma and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Lung Cancer, Lymphoma and Melanoma
This triple analysis focuses on cancer drug development strategies in Lung Cancer, Lymphoma and Melanoma. Learn More


Triple Analysis: Colorectal Cancer, Pancreatic Cancer and Apoptosis
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Pancreatic Cancer and by the mechanism/target/effect of Apoptosis. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Breast Cancer, Angiogenesis and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in Breast Cancer and by the two mechanism/target/effect areas of Angiogenesis and Cancer Vaccines. Learn More


Triple Analysis: Apoptosis, Protein Kinase Inhibitors and Antibodies
This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors and by the compound strategy of Antibodies. Learn More